SELLAS Life Sciences Group, Inc. (SLS)
Largest Insider Buys in Sector
SLS Stock Price History Chart
SLS Stock Performance
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Insider Activity of SELLAS Life Sciences Group, Inc.
Over the last 12 months, insiders at SELLAS Life Sciences Group, Inc. have bought $0 and sold $0 worth of SELLAS Life Sciences Group, Inc. stock.
On average, over the past 5 years, insiders at SELLAS Life Sciences Group, Inc. have bought $0 and sold $22,757 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $98,742 was made by Nisi Rudolph (director) on 2014‑02‑07.
List of Insider Buy and Sell Transactions, SELLAS Life Sciences Group, Inc.
| 2022-12-05 | Sale | Stergiou Angelos M. | President and CEO | 6,494 0.0347% | $2.61 | $16,938 | -37.30% | |
| 2022-12-05 | Sale | WOOD BARBARA A | EVP, Gen. Counsel, Corp. Sec. | 2,153 0.0114% | $2.59 | $5,576 | -37.30% | |
| 2022-12-05 | Sale | Burns John Thomas | Senior VP, Finance & CAO | 1,159 0.0061% | $2.59 | $3,002 | -37.30% | |
| 2021-12-02 | Sale | Stergiou Angelos M. | President and CEO | 2,120 0.0133% | $6.25 | $13,252 | -51.09% | |
| 2021-12-02 | Sale | WOOD BARBARA A | EVP, Gen. Counsel, Corp. Sec. | 847 0.0053% | $6.25 | $5,298 | -51.09% | |
| 2021-12-02 | Sale | Burns John Thomas | VP, Finance & Corp Controller | 231 0.0014% | $6.27 | $1,448 | -51.09% | |
| 2018-12-31 | Sale | Stergiou Angelos M. | President and CEO | 23,277 0.1061% | $1.25 | $29,189 | -86.59% | |
| 2017-06-20 | Sale | Nisi Rudolph | director | 500 0.0013% | $0.55 | $273 | -50.00% | |
| 2017-02-08 | Sale | Hudson Bay Capital Management LP | 10 percent owner | 2.36M 9.0582% | $0.84 | $1.99M | -50.00% | |
| 2014-02-12 | Sale | Chin Richard | director | 187,500 0.1611% | $4.33 | $812,438 | -48.39% | |
| 2014-02-07 | Nisi Rudolph | director | 20,000 0.0172% | $4.94 | $98,742 | -53.96% | ||
| 2014-02-03 | Sale | GALLIKER STEPHEN S | director | 300,000 0.2555% | $4.18 | $1.25M | -45.97% | |
| 2014-01-30 | Sale | SCHWARTZ MARK W. | EVP & Chief Operating Officer | 100,000 0.0885% | $5.57 | $556,500 | -57.67% | |
| 2014-01-30 | Sale | Hillsberg Sanford | director | 250,000 0.2151% | $5.41 | $1.35M | -57.67% | |
| 2014-01-30 | Sale | Chin Richard | director | 75,000 0.0666% | $5.58 | $418,755 | -57.67% | |
| 2014-01-29 | Sale | Nisi Rudolph | director | 250,000 0.2151% | $5.28 | $1.32M | -56.63% | |
| 2014-01-23 | Sale | KRIEGSMAN STEVEN A | director | 150,000 0.1251% | $5.92 | $888,540 | -62.36% | |
| 2014-01-22 | Sale | KRIEGSMAN STEVEN A | director | 250,000 0.2176% | $6.13 | $1.53M | -61.96% | |
| 2014-01-17 | Sale | Hillsberg Sanford | director | 200,000 0.1702% | $6.92 | $1.39M | -66.71% | |
| 2014-01-17 | Sale | KRIEGSMAN STEVEN A | director | 200,000 0.1721% | $7.00 | $1.4M | -66.71% |
Institutional Investor Ownership
| Anson Funds Management Lp | $4.88M | 8.37 | 4.83M | New | +$4.88M | 0.23 | |
| The Vanguard Group | $1.53M | 2.62 | 1.51M | +31.89% | +$369,570.03 | <0.0001 | |
| BlackRock | $281,000.00 | 0.48 | 278,218 | -0.57% | -$1,601.86 | <0.0001 | |
| Geode Capital Management | $275,867.00 | 0.47 | 273,063 | +11.18% | +$27,741.98 | <0.0001 | |
| Opus Capital Group Llc | $203,000.00 | 0.35 | 200,600 | +48.59% | +$66,384.85 | 0.03 | |
| Equitable Holdings | $202,000.00 | 0.35 | 200,000 | +21.21% | +$35,350.00 | <0.01 | |
| State Street | $98,100.00 | 0.17 | 97,129 | 0% | +$0 | <0.0001 | |
| Northern Trust | $89,618.00 | 0.15 | 88,730 | +42.11% | +$26,556.14 | <0.0001 | |
| Virtu Financial Llc | $40,000.00 | 0.07 | 39,429 | -34.19% | -$20,781.66 | <0.01 | |
| Mariner Llc | $25,510.00 | 0.04 | 25,257 | New | +$25,510.00 | <0.0001 | |
| Cantor Fitzgerald L P | $24,998.00 | 0.04 | 24,750 | New | +$24,998.00 | <0.0001 | |
| Tower Research Capital | $20,932.00 | 0.04 | 20,725 | +287.09% | +$15,524.52 | <0.0001 | |
| Citadel Advisors LLC | $19,915.00 | 0.03 | 19,718 | New | +$19,915.00 | <0.0001 | |
| Xtx Topco Ltd | $17,565.00 | 0.03 | 17,391 | -59.15% | -$25,430.92 | <0.01 | |
| Charles Schwab | $16,400.00 | 0.03 | 16,238 | 0% | +$0 | <0.0001 | |
| Brooklyn Fi Llc | $11,290.00 | 0.02 | 11,178 | New | +$11,290.00 | 0.01 | |
| JPMorgan Chase | $6,153.00 | 0.01 | 6,092 | -37.79% | -$3,738.06 | <0.0001 | |
| Advisor Group Holdings Inc | $1,676.00 | <0.01 | 1,660 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $1,434.00 | <0.01 | 1,420 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $304.00 | <0.01 | 301 | -98.16% | -$16,216.03 | <0.0001 | |
| Allworth Financial Lp | $152.00 | <0.01 | 150 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 223 | -37.71% | -$0 | <0.0001 | |
| Fidelity Investments | $1.00 | <0.01 | 1 | New | +$1.00 | <0.0001 | |
| Parkside Financial Bank & Trust | $3.00 | <0.01 | 2 | 0% | +$0 | <0.0001 | |
| JJJ Advisors Inc | $12.00 | <0.01 | 11 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 2 | 0% | +$0 | <0.0001 |